Central Bank to update inflation target in coming period: Source    Egypt's exports of chemical, fertiliser industries expected to reach EGP 8bn by year-end    FM Shoukry highlights repercussions of climate change during AOSIS meeting    FM Shoukry highlights repercussions of climate change during AOSIS meeting    Egypt seeks to achieve balanced results in international climate action: FM    Al-Sisi approves Egypt's bid to host 2036 Olympic Games    Al-Sisi approves Egypt's bid to host 2036 Olympic Games    Egypt's Al-Sisi directs development of basic education system    Health Minister inaugurates logistic complex for preserving vaccines at Vacsera    AUC signs MoU with GAHAR to build healthcare professionals' capacities‏‏    Prime Minister inspects Grand Egyptian Museum project    Prime Minister inspects Grand Egyptian Museum project    Egypt holds Food Africa exhibition's 7th session in Cairo    Hyde Park Developments showcases projects in east and west Cairo, North Coast at Cityscape Egypt exhibition    Egypt expects IMF approval of loan package next week    The godfather of CIB Egypt bank, Hisham Ezz Al-Arab, returns as chairman – Al Arabiya    K-pop creates mutual understanding between South Korea, Egypt: Korean Cultural Center    Angola's newly elected President appoints new Cabinet    Egypt's FM meets with his US counterpart on side-lines of UN General Assembly meetings    Irrigation Minister stresses importance of scientific research in water sector    MV Logos Hope floating library to arrive in Egypt in January 2023    Self-care matters – 36% of professional gamers in MENA, Turkiye, Africa worry about mental health condition    Amazon unveils blueprint to boost workplace inclusivity for people with disabilities in Egypt    Byline: Pressing save on the metaverse – the future of tangible experiences    Egypt holds its first championship in American dominoes    Dior showcases 2023 fall men's collection at Egypt's pyramids    US aquarium saves 150 sea turtles from cold    Tech giant Apple 'expresses interest' in acquiring Manchester United – report    Egypt operates solar-powered cars at 2 archaeological sites in Luxor    Egypt launches 200 Years of Continuing Science tourism campaign    QNB Group names TikToker Khaby Lame official FIFA World Cup Qatar 2022 brand ambassador    Three possible scenarios as Egypt's central bank governor resigns – MP    Adele is living a love story, wants to be a homemaker    In Photos: Egypt swears in 13 new ministers after major Cabinet reshuffle    Egypt's parliament approves Cabinet reshuffle in extraordinary session    Spain: prosecutor seeks 8 years sentence for Shakira over tax evasion    Russia says it's in sync with US, China, Pakistan on Taliban    It's a bit frustrating to draw at home: Real Madrid keeper after Villarreal game    Shoukry reviews with Guterres Egypt's efforts to achieve SDGs, promote human rights    Sudan says countries must cooperate on vaccines    Johnson & Johnson: Second shot boosts antibodies and protection against COVID-19    Egypt to tax bloggers, YouTubers    Egypt's FM asserts importance of stability in Libya, holding elections as scheduled    We mustn't lose touch: Muller after Bayern win in Bundesliga    Egypt records 36 new deaths from Covid-19, highest since mid June    Egypt sells $3 bln US-dollar dominated eurobonds    Gamal Hanafy's ceramic exhibition at Gezira Arts Centre is a must go    Italian Institute Director Davide Scalmani presents activities of the Cairo Institute for ITALIANA.IT platform    







Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.



Sanofi eyes approval of COVID-19 vaccine by first half of 2021
Published in Ahram Online on 23 - 06 - 2020

French drugmaker Sanofi SA said on Tuesday it expects to get approval for the potential COVID-19 vaccine it is developing with Britain's GlaxoSmithKline Plc by the first half of next year, faster than previously anticipated.
Sanofi, which is hosting a virtual research and development event, and GSK had said in April the vaccine, if successful, would be available in the second half of 2021.
"We are being guided by our dialogue with regulatory authorities," Sanofi research chief John Reed told reporters, when asked about the accelerated time frame.
There are currently no vaccines to prevent the coronavirus that has infected more than 9 million people and killed over 469,000 globally, and only a couple of medicines that have demonstrated benefit in hospitalized COVID-19 patients in clinical trials.
Many drugmakers are racing to come up with a safe and effective vaccine that can be produced at large scale.
Moderna Inc, the University of Oxford in collaboration with AstraZeneca Plc, and an alliance of BioNTech and Pfizer Inc grabbed headlines by moving to human trials as early as March.
Sanofi Chief Executive Paul Hudson said the firsts in the race now were not assured of securing victory.
"There are companies moving faster, but let us be brutally clear, speed has three downsides," he said of competition.
"They are using existing work, in many cases done for SARS; it is likely not to be as efficacious; and there is no guarantee on supply in large volumes," Hudson said.
The probability of success for Sanofi is "higher than anybody else," the CEO said.
The comments echoed those of GSK, whose chief medical officer for vaccines told Reuters on Friday the company was aiming at quality before speed.
Sanofi, whose Pasteur vaccines division has a long established reputation, notably in flu, is currently working on two vaccine projects.
One uses an adjuvant made by GSK to potentially boost its efficacy. It has received financial support from the U.S. Biomedical Advanced Research and Development Authority (BARDA).
The other, being developed with U.S. company Translate Bio Inc, relies on a different technology known as mRNA, similar to the Moderna approach.
Clinical trials of the vaccine developed with GSK, described as a recombinant vaccine because of the use of GSK's boosting adjuvant, are to start in September. Trials of the mRNA vaccine candidate should begin around the end of the year, the company said.
Sanofi said it had capacity to produce up to 1 billion doses a year of its recombinant vaccine, and that it would be able to supply up to 360 million doses of its mRNA vaccine annually.
In April, Sanofi said it had manufacturing capacity for 600 million doses for its recombinant vaccine, with the ambition to double production by mid-2021.
The company also said it would expand its collaboration with Translate Bio on developing vaccines, in a deal which will give the U.S. group $425 million in upfront payments.


Clic here to read the story from its source.